

1 **Effectiveness of one dose of killed oral cholera vaccine in an endemic**
2 **community in the Democratic Republic of the Congo: A matched case-control**
3 **study**

4 Espoir Bwenge Malembaka, MD PhD^{1,2}, Patrick Musole Bugeme, MD^{1,2}, Chloe Hutchins, PhD³,
5 Hanmeng Xu, MHS¹, Juan Dent Hulse, ScM¹, Maya N. Demby, BSc¹, Karin Gallandat, PhD³,
6 Jaime Mufitini Saidi, BSc⁴, Baron Bashige Rumedeka, BSc^{1,4}, Moïse Itongwa, BSc¹, Esperance
7 Tshiwedi-Tsilabia, MSc⁵, Faïda Kitoga, MSc⁵, Tavia Bodisa-Matamu, MD⁵, Hugo Kavunga-
8 Membo, MD PhD^{5,6}, Justin Bengheya, MPH⁷, Jean-Claude Kulondwa, MD⁷, Amanda K Debes,
9 PhD⁸, Nagède Taty, MD⁹, Elizabeth C. Lee, PhD¹, Octavie Lunguya MD PhD^{6,10}, Prof. Justin
10 Lessler, PhD^{1,11,12}, Daniel T Leung, MD^{13,14}, Oliver Cumming, MSc³, Placide Welo Okitayemba,
11 MD⁹, Daniel Mukadi-Bamuleka, MD PhD^{5,6,10}, Jackie Knee, PhD³, Andrew S Azman, PhD^{1,15,16*}

12 ¹*Department of Epidemiology, Johns Hopkins University, Baltimore, MD 21205, USA*

13 ²*Centre for Tropical Diseases and Global Health (CTDGH), Université Catholique de Bukavu,*
14 *Bukavu, Democratic Republic of the Congo*

15 ³*Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK*

16 ⁴*Ministère de la Santé Publique, Zone de Santé d'Uvira, Democratic Republic of Congo*

17 ⁵*Rodolphe Merieux INRB-Goma Laboratory, Goma, North-Kivu, Democratic Republic of the*
18 *Congo*

19 ⁶*Institut National de Recherche Biomédicale, INRB, Kinshasa, Democratic Republic of the*
20 *Congo*

21
22 ⁷*Ministère de la Santé Publique, Hygiène et Prévention, Division Provinciale de la Santé*
23 *Publique du Sud-Kivu, Democratic Republic of the Congo*

24 ⁸*Department of International Health, Johns Hopkins University, Baltimore, MD 21205, USA*

25 ⁹*PNECHOL-MD, Community IMCI, Ministry of Health, Democratic Republic of the Congo*

26 ¹⁰*Service of Microbiology, Department of Medical Biology, University of Kinshasa, Kinshasa,*
27 *Democratic Republic of the Congo*

28 ¹¹*University of North Carolina Population Center, University of North Carolina at Chapel Hill,*
29 *Chapel Hill, NC, USA*

30 ¹²*Department of Epidemiology, Gillings School of Global Public Health, University of North*
31 *Carolina at Chapel Hill, Chapel Hill, NC, USA*

32 ¹³*Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, Utah,*
33 *USA*

2

34 ¹⁴*Division of Microbiology and Immunology, University of Utah School of Medicine, Salt Lake*
35 *City, Utah, USA*

36

37 ¹⁵*Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva,*
38 *Switzerland*

39 ¹⁶*Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva,*
40 *Switzerland*

41 * Correspondence to:

42 Dr Andrew S Azman,
43 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
44 Johns Hopkins University, Baltimore, MD 21205, USA
45 azman@jhu.edu

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75 **Abstract**

76 **Background**

77 A global shortage of cholera vaccines has increased the use of single-dose regimens, rather than
78 the standard two-dose regimen. There is limited evidence on single-dose protection, particularly
79 in children. In 2020, a mass vaccination campaign resulting in largely single dose coverage, was
80 conducted in Uvira, an endemic urban setting in eastern Democratic Republic of the Congo. We
81 examined the effectiveness of a single-dose of the oral cholera vaccine Euvichol-Plus[®] in this
82 high-burden setting.

83 **Methods**

84 We recruited medically attended confirmed cholera cases and age-, sex-, and neighborhood-
85 matched community controls during two distinct periods after mass vaccination, October 2021 to
86 March 2022 (12–17 months post-vaccination) and October 2022 to October 2023 (24–36 months
87 post-vaccination). The odds of vaccination in cases and controls were contrasted in conditional
88 logistic regression models to estimate unadjusted and adjusted vaccine effectiveness.

89 **Findings**

90 We enrolled 658 confirmed cases and 2,274 matched controls during the two study periods with
91 15.0% of cases being under five years old at the time of vaccination. The adjusted single-dose
92 VE was 52.7% (95% CI: 31.4–67.4) 12–17 months post-vaccination and 45.5% (95% CI: 25.8–
93 60.0) 24–36 months post-vaccination. While protection in the first 12–17 months post-
94 vaccination was similar for 1–4-year-olds and older individuals, over the third year post-
95 vaccination the estimate of protection in 1–4 year-olds (adjusted VE 33.1%; 95% CI: -30.0–65.6)
96 appeared to wane with confidence intervals spanning the null.

97 **Interpretation**

98 A single-dose of Euvichol-Plus[®] provided substantial protection against medically attended
99 cholera for at least 36 months post-vaccination in this cholera endemic setting. While our
100 evidence provides support for comparable levels of protection in young children and others in the
101 short-term, protection among young children may wane significantly by the third year after
102 vaccination.

103 **Funding**

104 Wellcome Trust and Gavi (GAVI-RFP-2019-062).

105

106

107 **Research in context**

108 *Evidence before this study*

109
110 In late 2022, due to increasing demand for killed, whole-cell, oral cholera vaccines (kOCV)
111 and limited production capacity, the International Coordinating Group (the organization
112 managing emergency stocks of kOCVs) changed policy to deploy single-dose, rather than the
113 standard two-dose regimen, for emergency vaccination campaigns. This decision was in line with
114 WHO guidance on the use of a single dose in outbreaks, where short-term protection is key.
115 However, this recommendation is based on a limited number of clinical studies with short-term
116 follow-up. There is also limited evidence on the magnitude and duration of protection conferred
117 by a single dose of kOCV, particularly in children under five years of age.

118
119 We searched PubMed for randomized trials and observational studies published in English
120 before November 1, 2023, that reported estimates of protection conferred by a single dose of
121 kOCV, using the term “(effectiveness OR efficacy) AND cholera* AND vaccine”. We found no
122 published studies estimating the effectiveness of a single dose of Euvichol-Plus[®], and only one
123 study reporting two-dose effectiveness. Despite this paucity of evidence, this is the only vaccine
124 currently available in the global stockpile. To date, there has been one randomized trial
125 conducted in Bangladesh between 2014 and 2016, and seven observational studies conducted
126 between 2009 and 2016 in Guinea, Haiti, India, Malawi, Sudan, Zambia and Zanzibar, reporting
127 effectiveness estimates of a single dose of the current generation of kOCV. Aside from the trial
128 in Bangladesh, all estimates were based on secondary analyses that the studies were not powered
129 to estimate. The Bangladesh trial is the only study to date that provides an age-stratified estimate
130 of single-dose protection, and while it found an overall protective efficacy of 62% (95% CI: 43–
131 75) during the 2-year follow up for individuals aged five years or older, it found no significant
132 protection conferred by the Shanchol kOCV (a bioequivalent of Euvichol-Plus[®]) for individuals
133 under five years of age (protective efficacy: -44%, 95% CI -220 to 35). Four of the seven
134 observational studies provide single-dose vaccine effectiveness (VE) estimates only during the
135 first 12 months post-vaccination with estimates ranging from 43% (95% CI -84-82) in Guinea to
136 93% (95% CI 69-98) in Haiti. The three other observational studies providing a single dose VE
137 estimate between 12-30 months post- vaccination were unable to demonstrate statistically
138 significant protection conferred by kOCV, with estimates ranging between 32.5% (95% CI -
139 318.0-89.1) in India and 40% (95% CI -31-73) in Haiti. No vaccine protection estimates have
140 been published from the two identified cholera endemic foci in Africa, the Democratic Republic
141 of the Congo and Nigeria.

142 *Added value of this study*

143 In this vaccine effectiveness study, we show that a single dose of Euvichol-Plus[®] vaccine can
144 provide significant protection against medically attended cholera for up to 36 months
145 after vaccination in a cholera endemic setting in Africa, though protection in children under five
146 years old remains unclear. These estimates help fill critical gaps in our understanding of the
147 magnitude and duration of protection from a single dose of the most widely used kOCV,
148 Euvichol-Plus[®] and is one of only a few studies to measure protection in an endemic setting in
149 Africa.

150 *Implications of all the available evidence*

151 The corpus of available evidence suggests that use of a single dose of kOCV in
152 emergency situations where cholera is endemic, like Uvira, is justified and that providing a
153 second dose within the first 12-24 months post-vaccination may only provide marginal benefit to
154 the general population. However, more evidence and analyses are needed to weigh the costs and
155 benefits of tailored vaccination approaches for those under five years old, including possibility of
156 providing a second dose at an earlier timepoint.
157
158

159 **Introduction**

160 Safe water, sanitation, and hygiene (WASH) is the cornerstone of cholera prevention and control.
161 While universal access to safely-managed WASH services remains the ultimate priority, this is
162 likely a distant prospect.¹ Killed whole-cell oral cholera vaccine (kOCV) is an effective short-
163 term intervention to reduce cholera risk in high-burden settings and is a key component of the
164 global roadmap to end cholera.² kOCVs are typically delivered as a two-dose regimen that
165 provides protection for at least three years.^{3,4} In a meta-analysis of kOCV protection, estimated
166 two-dose efficacy was 58% (95% CI: 42 to 69), over an average of 28 months post-vaccination.
167 Lower protection was noted among young children.³

168 The Euvichol-Plus[®] vaccine (Eubiologics, Seoul, Republic of Korea) is currently the only WHO-
169 prequalified kOCV manufactured and included in the global stockpile after the Shanchol[®]
170 (Shantha Biotechnics, Hyderabad, India) ceased production in 2023.⁵ Euvichol-Plus[®] is
171 considered a bioequivalent of Shanchol[®].⁶ Almost all evidence of kOCV clinical protection is
172 based on the studies carried out on Shanchol[®],⁷⁻⁹ although one observational study explored the
173 protection conferred by a Euvichol-Plus[®] two-dose regimen.¹⁰

174 Demand for kOCVs outstripped the global supply in 2022, with only 33 million doses distributed
175 out of the 72 million requested.¹¹ In late 2022, the International Coordinating Group, which
176 manages the global emergency stockpile for cholera vaccines, suspended the provision of the
177 standard two-dose regimen in emergency vaccination campaigns, replacing it with a single-dose
178 regimen due to limited vaccine supply.¹² However, there are limited data on the protection
179 offered by one dose of kOCV over extended periods (>12 months) or among children 1-4 years
180 old.

181 Only a few studies have estimated single-dose protection in the general population, with point
182 estimates suggesting short-term protection up to 16 months after vaccination in Haiti, though
183 with large uncertainty.^{7-9,13-16} A randomized trial in Bangladesh, the only study to provide age-
184 stratified estimates of single-dose protection, suggested that Shanchol[®] conferred no protection
185 in 1-4 year-olds in the first six months post-vaccination, despite significant protection in older
186 individuals for at least two years.^{17,18}

187 In late 2020, the Ministry of Health of the Democratic Republic of the Congo (DRC) conducted
188 a mass vaccination campaign of Euvichol-Plus[®] in the city of Uvira in the South Kivu province.
189 The estimated coverage of the vaccination campaigns was low, and as most vaccinated
190 individuals reported receiving only one dose, we assessed effectiveness of a single dose of
191 kOCV during outbreaks that occurred 12-17 and 24-36 months after vaccination.

192 **Study design, setting and vaccination campaigns**

193 We conducted a matched case-control study in Uvira, a city of approximately 280,000
194 inhabitants on the northwestern shore of Lake Tanganyika with sporadic armed conflict, socio-

195 political instability, and population displacement. Cholera cases are detected year-round in Uvira
196 since 1978, often with distinct seasonal peaks and notable historical outbreaks.^{19,20} Household
197 surveys conducted in 2016/17 in Uvira indicated surface water as the main drinking water source
198 for 37.2% of households,²¹ and in areas close to the rivers and with the lowest tap water
199 availability, >80% of households use drinking water contaminated with *Escherichia coli*.²² The
200 same surveys estimated that about half (48.2%) of the population relied exclusively on tap water
201 for drinking needs²¹, and a recent study showed that between 2017 and 2021, the water service
202 quality remained suboptimal, or deteriorated in many parts of the city.^{23 20}

203 In April 2020, severe flooding caused at least 54 deaths, the displacement of approximately
204 80,000 people, and substantial damage to housing and WASH infrastructure in Uvira, prompting
205 the Ministry of Health to conduct emergency cholera vaccination campaigns.²⁴ Vaccination took
206 place in two rounds, from 29 July to 8 August and 28 September to 05 October 2020 targeting all
207 individuals in Uvira one year and older. The campaigns included door-to-door vaccination for
208 five days, followed by vaccination offered through health facilities. While two rounds of
209 vaccination were implemented, in a representative household survey we conducted 11 months
210 after vaccination, 23% (95% CI: 20-27%) of the participants reported receiving two doses of the
211 vaccine and 32% (95% CI: 38-36%) reported receiving one dose. No kOCV has been
212 administered in this population between these campaigns and the end of our study period, 18
213 October 2023.

214 **Clinical cholera surveillance system in Uvira**

215 Our study is based on enhanced clinical surveillance of cholera implemented at the two official
216 health facilities designated to treat cholera patients in Uvira, the cholera treatment centre at the
217 Uvira General Referral Hospital and the cholera treatment unit at the Kalundu CEPAC health
218 centre (henceforth, “CTCs”). We attempted to identify and recruit all patients at least 12 months
219 old with acute watery diarrhoea within the 24 hours prior to the admission to the CTCs (referred
220 to as ‘suspected cholera’). Trained healthcare staff collected rectal swabs and stools from
221 participants. Rectal swabs were enriched in alkaline peptone water (APW) for 6-18 hours
222 depending on patient admission time. Specimens were tested for *V. cholerae* by rapid diagnostic
223 tests (RDTs) onsite, and by culture using standard methods (Appendix) at either an in-country
224 reference laboratory, the Laboratoire Rodolphe Mérieux de l’Institut National de Recherche
225 Biomédicale (INRB), in Goma (from October 2021 to September 2022), or at the onsite study
226 laboratory (from September 2022 onward). As PCR for *V. cholerae* O1 was not available at
227 either study laboratory in DRC, we shipped stool specimens (stool spotted on dry filter papers)
228 for cases enrolled between October 14, 2021 and May 04, 2022 to Johns Hopkins University for
229 PCR detection of toxigenic *V. cholerae* O1 following published methods.²⁵

230 **Selection of cases and controls**

231 Two cholera outbreaks occurred after mass vaccination, and we recruited cases during each
232 outbreak, forming two distinct study periods (Figure 1). From 21 November 2022 to 24 January
233 2023, we retrospectively recruited controls for patients admitted to CTCs during the first
234 outbreak (14 October 2021 to 10 March 2022), approximately 12-17 months after the second
235 round of mass vaccination campaigns (Study Period 1). Between 17 October 2022 and 18
236 October 2023, we recruited controls for cases as they were admitted to the CTCs, 24-36 months
237 after vaccination (Study Period 2).

238 Study Period 1 (SP1) included all consenting suspected cases who were at least 12 months old
239 during the vaccination campaigns, living in Uvira for the two weeks prior to admission to the
240 CTC and during the 2020 vaccination campaigns, and who tested positive for cholera by culture
241 and/or PCR. We attempted to recruit four controls per case, using high-resolution satellite
242 imagery (Appendix) to identify potential control households on the same avenue (smallest
243 administrative unit in Uvira) as the case household. Control households were then selected by
244 simple random spatial sampling of digitized residential structures. Controls were eligible for
245 enrollment if: (1) they matched the case age group (1-4, 5-9, 10-19, 20-39, 40-59 or ≥ 60 years
246 old) and sex, (2) had not been admitted for acute watery diarrhoea or cholera in the three years
247 prior to the case admission, (3) were living in Uvira in the two weeks prior to case admission, (4)
248 were living in Uvira at the time of the 2020 kOCV campaign and were eligible to be vaccinated,
249 and (5) none of their household members reported being admitted to a formal health facility (as
250 opposed to pharmacies, prayer homes or traditional healers) for acute watery diarrhoea or cholera
251 in the four weeks prior to case admission (Table S1).

252 During Study Period 2 (SP2), the case definition included the same age and residence criteria as
253 in SP1, but cases had to test positive with both APW-enriched rapid diagnostic test (RDT) and
254 culture (performed at the onsite laboratory). We used enriched RDT results to help prioritize
255 control recruitment due to limited human resources during the outbreak. In contrast to SP1, we
256 conducted a home visit within three days of hospital discharge to investigate the living and
257 WASH conditions in each case's household and ascertain the vaccination status outside the
258 hospital environment (as done with the controls). We excluded patients who died during
259 hospitalization and those whose residence could not be found during home visits. As in SP1, four
260 neighborhood controls were recruited from four randomly selected households near the case
261 household, though during this study period we selected households using the 'right-hand' rule
262 (Appendix). In addition to the recruitment criteria used in SP1, controls were eligible for
263 enrolment in SP2 if their household matched that of the case by size (≤ 5 individuals, 6-10
264 individuals, and >10 individuals) and had at least one child below five years of age when the
265 case household had one.

266 **Vaccination status ascertainment and potential confounding variables**

267 Study staff administered structured questionnaires to all cases and controls (or their
268 parent/guardian) to capture demographics, household conditions, potential confounding variables

269 and vaccination status. Before asking each case or control whether they were vaccinated, study
270 staff showed them photos of the vaccine vials and of someone taking the vaccine, in addition to
271 explaining when and how the vaccines were delivered in Uvira, and how these may differ from
272 other campaigns and routine vaccines. Participants reporting vaccination were asked the number
273 of doses and when and where each one was taken. We also used vaccination cards to verify the
274 vaccination status whenever possible. In SP1, vaccine-related questions were asked to cases in
275 the clinic and in SP2 they were asked both in the clinic and a subsequent home visit. Any
276 differences in the vaccination status reporting between the clinic and household interviews were
277 solved through a third interview at the case's household followed by a review of the data,
278 discussion, and consensus within the study team. We identified potential confounders based on a
279 causal directed acyclic graph developed before the start of the study and attempted to measure
280 these through the interviews.

281 **Statistical analyses**

282 The characteristics of case and control participants were compared using the standardized mean
283 difference (SMD), which is the absolute difference in mean values of a variable between cases
284 and controls divided by the pooled standard deviation. In addition, we calculated p-values from
285 univariate conditional logistic regression models with case-control status as the dependent
286 variable. In the primary analysis, we compared the odds of being vaccinated with a single kOCV
287 dose between cases and controls using conditional logistic regression models. Those reporting to
288 have received 2 or more doses were dropped from the primary analyses. The vaccine
289 effectiveness (VE) was calculated as one minus the estimated odds ratio of having received a
290 single dose of vaccine, between cases and controls. To produce consistent age-group specific and
291 overall estimates of effectiveness across all ages, the conditional logistic regression model
292 included an interaction term for age group (1-4 vs. ≥ 5) and the vaccination status. We derived the
293 overall VE estimate based on a linear combination of parameters from the two age groups,
294 weighted by the proportion of cases within each, and estimated simultaneous confidence
295 intervals with the *ghlt* function in the *multcomp* R package.²⁶ For continuous variables, we
296 explored models using polynomials and restricted cubic splines, and compared them using
297 Akaike Information Criterion (AIC). For combined estimates (SP1/2) and those from SP1, we
298 incorporated age as a continuous variable, separately by the two age groups (with a quadratic
299 term for the age group ≥ 5 years), to adjust for potential confounding. For SP2, estimates were
300 adjusted for a set of potential confounders including a quadratic term for age, a cubic term for
301 household size, household wealth index (as a continuous variable) derived from a principal
302 component analysis of household assets ownership (Appendix), type of sanitation facility,
303 whether the participant used a toilet shared by multiple households compared to using a private
304 toilet, drinking water sources, and availability of a hand washing facility and soap. We also fit
305 three alternative models with different sets of covariates to assess the robustness of the estimates
306 (Appendix). In a secondary analysis, we estimated the VE for at least one dose and two doses of
307 kOCV compared to the unvaccinated group. While we primarily relied on point estimates and

308 95% confidence intervals (CI) to assess the weight of evidence, we considered p-values
309 statistically significant when they were less than 0.05. Analyses were performed in R (version
310 4.3.1).

311 **Ethical considerations**

312 Ethical approvals were obtained from Institutional Review Boards of the Johns Hopkins
313 Bloomberg School of Public Health (IRB00015785), the London School of Hygiene & Tropical
314 Medicine (25365) and the École de Santé Publique at the University of Kinshasa
315 (ESP/CE/65/2021). Written informed consent was obtained from all participants ≥ 18 years, with
316 written assent from those < 18 years in addition to written consent from their parent/guardian.


317 **Role of the funding source**

318 The funders of the study had no role in study design, data analysis, interpretation, preparation of
319 this manuscript, or the decision to publish.

320 **Results**

321 **Cholera incidence in Uvira and recruitment of study participants**

322
323 We recruited 658 unique confirmed cholera cases and 2,274 matched controls during the two
324 study periods (Figure 1), with 61.1% of cases enrolled in the second period. The median age of
325 participants at the time of the vaccination campaigns was 14.9 (interquartile range 6.3, 33.8)
326 years and 15.1% were under five years old (Table 1). Almost sixty-two percent of cases were
327 recorded as severely dehydrated on admission. Cases were significantly older during the first
328 study period compared to the second period ($p=0.005$), though they all had similar dehydration
329 status (Table S2). Of the 537 culture positive isolates, 390 (72.6%) were serotype Ogawa, the
330 rest were Inaba, including 19.3% ($n=26/135$) Inaba in SP1 and 30.1% ($n = 121/402$) Inaba in
331 SP2.




332
333 **Figure 1. Number of cholera cases admitted to cholera treatment facilities in Uvira.** Panels A
334 (Study Period 1) and B (Study Period 2) illustrate the cumulative number of confirmed cases in each study
335 period by neighborhood (avenue) across the city, with the locations of the two health facilities where patients
336 were recruited shown as dots. There were 14 cases living in neighboring communities outside the city
337 boundaries that were included in Study Period 2. The second outbreak (Study Period 2) started in the northern
338 part of the city and spread to a refugee camp where many residents were admitted to the CTC but not included
339 in the study as they were not living in Uvira at the time of vaccination. Panel C illustrates the epidemic curve
340 of suspected and confirmed cholera cases admitted to the cholera treatment center (CTC) at the Uvira General
341 Referral Hospital and the cholera treatment unit (CTU) at the Kalundu CEPAC health center. Cholera was
342 confirmed by culture or PCR (Study Period 1), or by APW-enriched RDT and culture (Study Period 2).
343 Among the 183 suspected cases that were detected before SP1 (in grey), 146 (79.8%) were tested for *Vibrio*
344 *cholerae* O1 by enriched RDT with 37 (25.3%) testing positive.

345
346 Overall, 20.2% of cases reported receiving one dose of kOCV and 68.7% were unvaccinated. In
347 comparison, 31.6% of matched controls reported receiving a single dose of kOCV and 56.3%

12

348 were unvaccinated. Only 13.6% of vaccinated participants were able to show a vaccination card
349 and 11.9% reported having received two doses of the vaccine (Table 1).

350



351 **Figure 2.** Flow chart of participant recruitment. Cases with unavailable culture results are those
352 for which 1) suspected colonies were isolated, 2) with positive oxidase test at the field
353 laboratory, 3) missing agglutination results due to an antiserum stockout, 4) and/or in which
354 attempts to revitalize *Vibrio cholerae* O1 strains at the reference laboratory in Goma were
355 unsuccessful.
356

357

358

359

360 **Table 1. Characteristics of participants by case and control status.**

Characteristic	Overall, N = 2,932	Cases, N = 658	Controls, N = 2,274	P value	SMD
Age at vaccination, median (IQR)	14.9 (6.3, 33.8)	14.1 (6.0, 33.8)	15.1 (6.4, 33.7)	0.0019	0.005
Age group at vaccination (years)					0.122
1-4	443 (15.1%)	99 (15.0%)	344 (15.1%)	Reference	
5-9	552 (18.8%)	146 (22.2%)	406 (17.9%)	0.0080	
10-19	764 (26.1%)	159 (24.2%)	605 (26.6%)	0.7183	
20-39	606 (20.7%)	124 (18.8%)	482 (21.2%)	0.8436	
40-59	401 (13.7%)	91 (13.8%)	310 (13.6%)	0.4146	
≥60	166 (5.7%)	39 (5.9%)	127 (5.6%)	0.4495	
Sex					0.001
Female	1,503 (51.3%)	337 (51.2%)	1,166 (51.3%)	Reference	
Male	1,429 (48.7%)	321 (48.8%)	1,108 (48.7%)	0.8577	
Vaccination status					0.277
Not Vaccinated	1,732 (59.1%)	452 (68.7%)	1,280 (56.3%)	Reference	
One Dose	851 (29.0%)	133 (20.2%)	718 (31.6%)	<0.0001	
Two Doses	349 (11.9%)	73 (11.1%)	276 (12.1%)	0.0110	
Vaccination card available	163 (13.6%)	29 (14.1%)	134 (13.5%)	0.1092	0.017

361 P values are obtained from univariable conditional logistic regression models.

362 Additional data on socio-demographic and household characteristics were collected in SP2
 363 (Table 2, Table S4). Cases were more likely to use toilets shared by multiple households than
 364 controls (OR 1.41; 95% CI 1.11-1.79) and were less likely to live in houses with electricity (OR
 365 0.72; 95% CI 0.56-0.92). Cases were also more likely to live in households with lower wealth
 366 index, indicating higher level of poverty (OR 0.58; 95% CI 0.44-0.76) than controls. Although
 367 likely an artifact of hygiene kit distribution that focused on case households, we found that cases
 368 were more likely to live in households with soap and water available for handwashing (OR 1.86;
 369 95% CI 1.40-2.49).

370

371

372

373

374

375

376 **Table 2. Characteristics of study participants in the vaccine effectiveness analysis 24-36**
 377 **months after vaccination (Study Period 2)**

Characteristic	Overall, N = 1,852	Cases, N = 402	Controls, N = 1,450	P value	SMD
Age group at vaccination (years)*					0.179
1-4	295 (15.9%)	60 (14.9%)	235 (16.2%)	Reference	
5-9	401 (21.7%)	109 (27.1%)	292 (20.1%)	0.0563	
10-19	466 (25.2%)	90 (22.4%)	376 (25.9%)	0.3003	
20-39	350 (18.9%)	67 (16.7%)	283 (19.5%)	0.0738	
40-59	245 (13.2%)	55 (13.7%)	190 (13.1%)	0.4303	
≥60	95 (5.1%)	21 (5.2%)	74 (5.1%)	0.4427	
Sex					0.005
Female	987 (53.3%)	215 (53.5%)	772 (53.2%)	Reference	
Male	865 (46.7%)	187 (46.5%)	678 (46.8%)	0.9500	
Education attainment**					0.353
None or primary	190 (28.4%)	52 (41.3%)	138 (25.5%)	Reference	
Lower secondary	119 (17.8%)	21 (16.7%)	98 (18.1%)	0.0277	
Upper secondary	319 (47.8%)	46 (36.5%)	273 (50.4%)	0.0008	
Bachelor or higher	40 (6.0%)	7 (5.6%)	33 (6.1%)	0.3492	
Occupation					0.113
No work	289 (15.6%)	71 (17.7%)	218 (15.0%)	Reference	
Preschool children	197 (10.6%)	45 (11.2%)	152 (10.5%)	0.5777	
Students	822 (44.4%)	180 (44.8%)	642 (44.3%)	0.7115	
Informal work	455 (24.6%)	92 (22.9%)	363 (25.1%)	0.1483	
Salaried	88 (4.8%)	14 (3.5%)	74 (5.1%)	0.0425	
Missing	1	0	1		
Household size, median (IQR)	7.0 (6.0, 9.0)	7.0 (5.3, 9.0)	7.0 (6.0, 9.0)	0.2162	0.066
Drinking water source					0.033
Improved	1,037 (56.0%)	220 (54.7%)	817 (56.4%)	Reference	
Unimproved	814 (44.0%)	182 (45.3%)	632 (43.6%)	0.4573	
Missing	1	0	1		
Living in household with shared toilet					0.154
Private	843 (45.5%)	159 (39.6%)	684 (47.2%)	Reference	
Shared	1,009 (54.5%)	243 (60.4%)	766 (52.8%)	0.0049	
Toilet type					0.085
Improved	1,265 (68.3%)	262 (65.2%)	1,003 (69.2%)	Reference	

				e	
Unimproved	587 (31.7%)	140 (34.8%)	447 (30.8%)	0.1117	
Soap and water available for handwashing	881 (47.6%)	217 (54.0%)	664 (45.8%)	<0.0001	0.164
Living in household with electricity	782 (42.2%)	150 (37.3%)	632 (43.6%)	0.0090	0.128
Wealth index, median (IQR) ***	0.7 (-39.2, 36.3)	-5.3 (-50.0, 31.3)	2.7 (-30.9, 36.5)	0.0001	0.182
Vaccination status					0.244
Not Vaccinated	1,125 (60.7%)	275 (68.4%)	850 (58.6%)	Reference	
One Dose	525 (28.3%)	81 (20.1%)	444 (30.6%)	<0.0001	
Two Doses	202 (10.9%)	46 (11.4%)	156 (10.8%)	0.3868	
Vaccination card available	102 (14.1%)	22 (17.9%)	80 (13.4%)	0.0252	0.125

378 *Age group refers to the age on the first day of the second mass vaccination campaign round (01 October
 379 2020). **The question about education attainment was only asked to individuals aged ≥ 18 years. ***
 380 Wealth index was multiplied by 100. The higher the wealth index the richer the household. The
 381 distribution of age and sex of the cases and controls does not match perfectly because the number of
 382 controls included for each case varied slightly due to enrolled controls either not meeting the eligibility
 383 criteria (e.g., not living in Uvira during vaccination) or not recalling their vaccination status. P values are
 384 obtained from univariable conditional logistic regression models.
 385
 386

387 Combining data from both study periods, 12-36 months post-vaccination, we estimated an
 388 unadjusted single-dose VE of 47.8% (95% Confidence Interval [CI] 34.6–58.4) and after
 389 adjustment for potential confounders, the VE was 48.2% (95% CI 34.8–58.8).

390 In SP1, 12–17 months after vaccination, we estimated an unadjusted and adjusted single-dose
 391 VE of 54.4% (95% CI: 34.4–68.3) and 52.7% (95% CI: 31.4–67.4). In SP2, 24–36 months after
 392 vaccination, we estimated an unadjusted VE of 43.2% (95% CI: 24.0–57.6) and an adjusted VE
 393 of 45.5% (95% CI: 25.8–60.0). The adjusted VE for 1–4-year-olds was 73.5% (95% CI: 28.9–
 394 90.1) in SP1 sharply declining to 33.1% (95% CI: -30.0–65.6) in SP2 and the confidence
 395 intervals span the null (Table 3).

396
 397 **Table 3. Effectiveness of a single dose of oral cholera vaccine, 12-17 months and 24-36**
 398 **months after vaccination campaigns.**

Population	Cases (effective n*)	Controls (effective n*)	Unadjusted VE (95% CI)	Adjusted VE** (95% CI)
12-36 months after vaccination				
Overall	573 (419)	1998 (763)	47.8% (34.6–58.4)	48.2% (34.8–58.8)
1-4 years	96 (61)	263 (129)	52.4% (22.5–70.8)	49.8% (15.6–70.2)
≥ 5 years	463 (332)	1534 (584)	46.7% (31.8–58.4)	47.8% (32.8–59.5)
12-17 months after vaccination (Study Period 1)				

Overall	219 (170)	704 (300)	54.4% (34.4–68.3)	52.7% (31.4–67.4)
1-4 years	34 (23)	83 (44)	68.3% (19.6–87.5)	73.5% (28.9–90.1)
≥5 years	179 (141)	568 (243)	50.9% (28.0–66.6)	46.9% (21.0–64.3)
24-36 months after vaccination (Study Period 2)				
Overall	354 (249)	1294 (463)	43.2% (24.0–57.6)	45.5% (25.8–60.0)
1-4 years	62 (38)	180 (85)	42.8% (-2.2–68.0)	33.1% (-30.0–65.6)
≥5 years	284 (191)	966 (341)	43.4% (21.7–59.0)	48.3% (27.2–63.3)

399 *Effective number of cases and controls is the sample size that effectively contributes to estimates of effectiveness in
400 the conditional logistic regression models. Those participants in matched case-control sets where all people have the
401 same vaccination status do not contribute to the estimates, nor do those who either do not know their vaccination
402 status or the number of doses they received. **In SPI and in analyses combining data from both study periods, we
403 only adjusted for age as a continuous variable

404 In secondary analyses, we estimated the adjusted cumulative VE across both study periods for at
405 least one dose of kOCV to be 45.4% (95% CI: 33.2–55.3, Table S8). We were unable to
406 reliably estimate two-dose VE due to a limited effective sample size, with post-hoc power
407 calculations suggesting we had 50.9% power to detect significant vaccine protection even when
408 combining data from both study periods and 5.1% power in young children (Table S9, Table
409 S10).

410 Discussion

411 We found that a single dose of Euvichol-Plus[®] kOCV provided protection against cholera for at
412 least the 36-month period post-vaccination. Our study provides unique, policy-relevant insights
413 into kOCV protection as we estimated single-dose effectiveness from the only available and
414 most widely used cholera vaccine today, including estimates of effectiveness for 1–4-year-olds
415 and at discrete time windows after vaccination. Our results suggest that at least in cholera
416 endemic areas like Uvira, the use of one kOCV dose may provide significant protection on the
417 scale of years rather than just months.

418
419 To date, one randomized trial^{17,18} and seven observational studies have included estimates of
420 one-dose protection of kOCVs.^{7–9,13–15,27} Most of these studies have been short-term estimates of
421 protection measured for just a few months after vaccination and showed similar levels of
422 protection to two doses on this timescale. Two notable exceptions where protection was
423 measured over a longer period include a randomized trial in Bangladesh and a case-control study
424 in Haiti, both using Shanchol[®]. The Bangladesh trial was conducted for two years and estimated
425 54% (95% CI: 16 to 75) efficacy in the first year and 67% (43 to 81) in the second year post-
426 vaccination among those five years and older.¹⁷ Secondary analyses from a case-control study in
427 Haiti predicted that a single dose of kOCV (Shanchol[®]) would confer 58% (95% CI: 4 to 82%)
428 protection at 16 months post-vaccination, with the confidence intervals including zero protection
429 from 17-months post-vaccination and onward.¹⁴ Our results are consistent with these previous
430 studies in showing significant protection for the overall population for longer than a year, though
431 it is important to note that Uvira, like Haiti (at the time of the study) and Bangladesh, is endemic
432 for cholera so the first dose may have acted as a booster for previously exposed individuals.

433 Furthermore, it is possible that previous exposures to enterotoxigenic *Escherichia coli*, which has
434 been identified among diarrhoea cases in Uvira and has a antigenically similar toxin to toxigenic
435 *V. cholerae*, could contribute to background immunity to severe disease in these settings.²⁸ More
436 work is needed to characterize the epidemiologic settings where one dose may provide
437 comparable levels of protection to the full regimen, and might include leveraging historic
438 incidence rates of cholera or, perhaps, population-level immunologic measures of previous
439 exposures.²⁹

440 Before this study, only one estimate of single-dose protection of a kOCV in 1–4-year-olds had
441 been published. This trial, in Bangladesh, suggested that young children did not benefit from a
442 single dose of Shanchol[®], even during the first six months post-vaccination.^{17,18} In contrast, we
443 found evidence that the population under five years old in Uvira benefited from similar levels of
444 protection to those five and above at 12-17 months post-vaccination, however the point estimates
445 dropped substantially in the third year after vaccination with confidence intervals spanning the
446 null. This observation is in line with studies showing similar levels of protection after natural
447 infection between the two age groups.³⁰ Conflicting estimates between young children and older
448 individuals have also been observed in kOCV studies with the full dose regimen, though there
449 are only a handful of studies that present age-stratified estimates. Although most studies have
450 found lower effectiveness in young children, the difference in protection has been highly variable
451 with large uncertainty (e.g., ranging from no apparent difference in Vietnam after 10 months,³¹ to
452 73% lower protective efficacy among children in Bangladesh over 6 months post-vaccination¹⁸).
453 The contrast of our estimates with other studies could be explained by several factors including
454 pre-existing population immunity and season of vaccination as shown with other diseases,³²
455 differences both in gut microbiota composition and in prevalence of enteropathy, however, as in
456 all observational studies we cannot rule out confounding and selection bias.^{33,34} Additional
457 observational, and ideally randomized trials, would help shed further light on protection of one
458 dose of kOCV among young children.

459 While the focus of the study was to understand the direct effectiveness of kOCV, our analysis of
460 potential risk factors highlighted key differences between cases and matched controls. Our
461 results confirm the associations between cholera and markers of poverty, like using a shared
462 latrine, using an unimproved source for drinking water and not having electricity in the
463 household. While kOCV provides protection against cholera, tackling fundamental risk factors
464 like access to safe water and sanitation are needed to sustainably control the disease.

465 This study comes with several limitations. First, like many previous kOCV effectiveness studies,
466 the vaccination status was self-reported,^{7,14,15} and only 29 cases (of 206 reporting to be
467 vaccinated) were able to provide a vaccination card. Measurements of the number of doses
468 received months to years after a mass vaccination campaign is prone to recall bias, particularly in
469 a place like Uvira where mass vaccination campaigns with different antigens are common. To
470 minimize biases in classification of vaccination status, we used visual aids and a series of
471 structured questions, and hospital and study staff reassured patients that their responses to the

472 study questions would in no way affect their care. Though enumerators were not blinded to the
473 vaccination status of the cases while enrolling their matched controls, the vaccine coverage
474 among controls was similar to that measured in community coverage surveys (Table S12).
475 Furthermore, sensitivity analyses restricted to only those with a vaccination card revealed similar
476 effectiveness estimates (Table S5). There were slight differences in the protocols of the case-
477 control study in each study period, challenging the interpretability of the joint estimates from
478 both periods. However, in sensitivity analyses simulating similar diagnostic criteria for cases in
479 SP1 and SP2, our qualitative findings remained consistent (Table S11). The retrospective
480 recruitment of controls for cases admitted during the SP1 precluded adjustment for individual
481 and household factors that may have influenced cholera disease risk or vaccine acceptability.
482 However, such factors are unlikely to have significantly influenced the magnitude of our VE
483 estimates as we observed in the SP 2 (Table S6 and S7) and other cholera VE studies conducted
484 elsewhere.^{7,14,15} The retrospective nature of recruitment of controls in SP1 could also have led to
485 differential recall of vaccination status among cases and their controls. Even in SP2, our VE
486 estimates could still be confounded by unmeasured factors. Although the number of cases under
487 five years of age was higher than in most published VE studies, our sample size in this important
488 age group was still small and led to wide confidence intervals around VE estimates (Table S2
489 and S10). Finally, we were unable to obtain reliable estimates of two dose protection partly
490 because few cases reported receipt of two doses of kOCV due to low vaccination coverage in the
491 population, and potentially because of uncertainty in the reporting of more than one dose of
492 kOCV (Tables S2, S3 S9 and Figure S2).

493
494 Our findings, combined with data from dose-interval studies conducted in Cameroon and
495 Zambia^{35,36}, suggest that providing a second dose a year or more after the first could lead to
496 better and longer lasting protection against cholera than the current two-dose series, at least
497 among older children and adults. While more data are needed across different settings and for
498 longer periods of time, our study extends the current evidence base on protection from a single-
499 dose of kOCV, and more specifically on protection from Euvichol-Plus[®], the most widely used
500 cholera vaccine available today.

501
502
503
504
505
506
507
508
509

510 **Declarations**

511 *Funding*

512 This work was supported by the Wellcome Trust and Gavi (GAVI-RFP-2019-062).

513 *Authors' contributions*

514 Conceptualization: EBM, ASA, JK. Data curation: EBM, JDH, HX, CH, PMB, ASA. Formal
515 analysis: EBM, ASA. Data interpretation: EBM, ASA, JK, JL, EL. Funding acquisition: ASA,
516 KG, OC. Investigation: EBM, PMB, CH, HX, JDH, BBR, MI, ETT, FK, TBM, AD, EL, DL, JK,
517 ASA. Methodology: EBM, ASA, CH, JK. Project Administration: EBM, PMB, MD, DMB,
518 HKM, CH, ASA, KG. Resources: PWO, JMS, DMB, AD, JK, OL. Software: EBM, JDH, HX,
519 ASA. Supervision: ASA, JK. Validation: EBM, ASA. Visualization - EBM, ASA. Writing -
520 original draft - EBM, ASA. Writing: review & editing: all authors.

521 *Acknowledgements*

522 We are thankful to Faraja Masema Lulela, Joël Faraja Zigashane Mashauri, Jean-Marie
523 Masugamuhanya Cirhonda, the CTCs nurses and field investigators for their support for the data
524 collection. We also thank the Head of the Uvira Health Zone, Dr Panzu Nimi, and the Director of
525 the Uvira General Referral Hospital, Dr Salomon Mashupe, for their operational and
526 administrative support throughout this study. We would also like to thank the MSF GIS Centre,
527 including Frederic Ham and Edith Rogenhofer, for their assistance with acquiring satellite
528 imagery data and Ahmad Alobaidi for assistance with dwelling extractions from this imagery.

529 *Data sharing*

530 Code and data from this study are available at
531 https://github.com/HopkinsIDD/uvira_onedose_ocv_ve.
532

533 **References**

- 534 1 Deshpande A, Miller-Petrie MK, Lindstedt PA, *et al*. Mapping geographical inequalities in access to
535 drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. *The*
536 *Lancet Global Health* 2020; **8**: e1162–85.
- 537 2 World Health Organization. Global Task Force on Cholera Control. Ending Cholera, a Global
538 Roadmap to 2030. World Health Organization, 2017.
- 539 3 Bi Q, Ferreras E, Pezzoli L, *et al*. Protection against cholera from killed whole-cell oral cholera
540 vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2017; **17**: 1080–8.
- 541 4 Ali M, Qadri F, Kim DR, *et al*. Effectiveness of a killed whole-cell oral cholera vaccine in
542 Bangladesh: further follow-up of a cluster-randomised trial. *Lancet Infect Dis* 2021; **21**: 1407–14.
- 543 5 Burki T. Addressing the shortage of cholera vaccines. *Lancet Infect Dis* 2022; **22**: 1674–5.
- 544 6 Odevall L, Hong D, Digilio L, *et al*. The Euvichol story - Development and licensure of a safe,
545 effective and affordable oral cholera vaccine through global public private partnerships. *Vaccine*

- 546 2018; **36**: 6606–14.
- 547 7 Luquero FJ, Grout L, Ciglenecki I, *et al.* Use of *Vibrio cholerae* vaccine in an outbreak in Guinea. *N*
548 *Engl J Med* 2014; **370**: 2111–20.
- 549 8 Azman AS, Parker LA, Rumunu J, *et al.* Effectiveness of one dose of oral cholera vaccine in
550 response to an outbreak: a case-cohort study. *Lancet Glob Health* 2016; **4**: e856–63.
- 551 9 Grandesso F, Kasambara W, Page A-L, *et al.* Effectiveness of oral cholera vaccine in preventing
552 cholera among fishermen in Lake Chilwa, Malawi: A case-control study. *Vaccine* 2019; **37**: 3668–
553 76.
- 554 10 Sialubanje C, Kapina M, Chewe O, *et al.* Effectiveness of two doses of Euvichol-plus oral cholera
555 vaccine in response to the 2017/2018 outbreak: a matched case-control study in Lusaka, Zambia.
556 *BMJ Open* 2022; **12**: e066945.
- 557 11 World Health Organization. Weekly epidemiological record. World Health Organization, 22
558 SEPTEMBER 2023, 98th YEAR <https://iris.who.int/handle/10665/372986> (accessed Oct 17, 2023).
- 559 12 World Health Organization. Shortage of cholera vaccines leads to temporary suspension of two-dose
560 strategy, as cases rise worldwide. 2022; published online Oct 19. [https://www.who.int/news/item/19-
561 10-2022-shortage-of-cholera-vaccines-leads-to-temporary-suspension-of-two-dose-strategy--as-
562 cases-rise-worldwide](https://www.who.int/news/item/19-10-2022-shortage-of-cholera-vaccines-leads-to-temporary-suspension-of-two-dose-strategy--as-cases-rise-worldwide) (accessed March 24, 2023).
- 563 13 Khatib AM, Ali M, von Seidlein L, *et al.* Effectiveness of an oral cholera vaccine in Zanzibar:
564 findings from a mass vaccination campaign and observational cohort study. *Lancet Infect Dis* 2012;
565 **12**: 837–44.
- 566 14 Franke MF, Ternier R, Jerome JG, Matias WR, Harris JB, Ivers LC. Long-term effectiveness of one
567 and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control
568 study. *Lancet Glob Health* 2018; **6**: e1028–35.
- 569 15 Ferreras E, Blake A, Chewe O, *et al.* Alternative observational designs to estimate the effectiveness
570 of one dose of oral cholera vaccine in Lusaka, Zambia. *Epidemiol Infect* 2020; **148**: e78.
- 571 16 Ivers LC, Hilaire IJ, Teng JE, *et al.* Effectiveness of reactive oral cholera vaccination in rural Haiti: a
572 case-control study and bias-indicator analysis. *Lancet Glob Health* 2015; **3**: e162–8.
- 573 17 Qadri F, Ali M, Lynch J, *et al.* Efficacy of a single-dose regimen of inactivated whole-cell oral
574 cholera vaccine: results from 2 years of follow-up of a randomised trial. *Lancet Infect Dis* 2018; **18**:
575 666–74.
- 576 18 Qadri F, Wierzbica TF, Ali M, *et al.* Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in
577 Bangladesh. *N Engl J Med* 2016; **374**: 1723–32.
- 578 19 Bugeme PM, Xu H, Hutchins C, *et al.* Cholera deaths during outbreaks in Uvira, Eastern Democratic
579 Republic of Congo, September 2021-January 2023. bioRxiv. 2023; published online June 3.
580 DOI:10.1101/2023.05.26.23290528.
- 581 20 Schyns C, Fossa A, Mutombo-Nfenda, *et al.* Cholera in Eastern Zaire, 1978. *Ann Soc Belg Med Trop*
582 1979; **59**: 391–400.
- 583 21 Jeandron A. Tap water access and its relationship with cholera and other diarrhoeal diseases in an

- 584 urban, cholera-endemic setting in the Democratic Republic of the Congo. 2020; published online
585 Dec 12. DOI:10.17037/PUBS.04659288.
- 586 22 Jeandron A, Cumming O, Kapepula L, Cousens S. Predicting quality and quantity of water used by
587 urban households based on tap water service. *npj Clean Water* 2019; **2**: 1–9.
- 588 23 Gaiffe M, Dross C, Malembaka EB, Ross I, Cumming O, Gallandat K. A fuzzy inference-based
589 index for piped water supply service quality in a complex, low-income urban setting. *Water Res*
590 2023; : 120316.
- 591 24 Gallandat K, Macdougall A, Jeandron A, *et al.* 1 Improved water supply infrastructure to reduce
592 acute diarrhoeal diseases and 2 cholera in Uvira, Democratic Republic of the Congo: results and
593 lessons learned 3 from a pragmatic trial. <https://osf.io/na47d/download> (accessed July 23, 2023).
- 594 25 Debes AK, Ateudjieu J, Guenou E, *et al.* Clinical and Environmental Surveillance for *Vibrio*
595 *cholerae* in Resource Constrained Areas: Application During a 1-Year Surveillance in the Far North
596 Region of Cameroon. *Am J Trop Med Hyg* 2016; **94**: 537–43.
- 597 26 Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. *Biom J* 2008;
598 **50**: 346–63.
- 599 27 Wierzbica TF, Kar SK, Mogasale VV, *et al.* Effectiveness of an oral cholera vaccine campaign to
600 prevent clinically-significant cholera in Odisha State, India. *Vaccine* 2015; **33**: 2463–9.
- 601 28 Clemens JD, Sack DA, Harris JR, *et al.* Cross-Protection by B Subunit-Whole Cell Cholera Vaccine
602 Against Diarrhea Associated with Heat-Labile Toxin-Producing Enterotoxigenic *Escherichia coli*:
603 Results of a Large-Scale Field Trial. *J Infect Dis* 1988; **158**: 372–7.
- 604 29 Azman AS, Lessler J, Luquero FJ, *et al.* Estimating cholera incidence with cross-sectional serology.
605 *Sci Transl Med* 2019; **11**. DOI:10.1126/scitranslmed.aau6242.
- 606 30 Ali M, Emch M, Park JK, Yunus M, Clemens J. Natural Cholera Infection–Derived Immunity in an
607 Endemic Setting. *J Infect Dis* 2011; **204**: 912–8.
- 608 31 Trach DD, Clemens JD, Ke NT, *et al.* Field trial of a locally produced, killed, oral cholera vaccine in
609 Vietnam. *Lancet* 1997; **349**: 231–5.
- 610 32 Moore SE, Collinson AC, Fulford AJC, *et al.* Effect of month of vaccine administration on antibody
611 responses in The Gambia and Pakistan. *Trop Med Int Health* 2006; **11**: 1529–41.
- 612 33 Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. *Clin*
613 *Microbiol Rev* 2019; **32**. DOI:10.1128/CMR.00084-18.
- 614 34 Porras AM, Shi Q, Zhou H, *et al.* Geographic differences in gut microbiota composition impact
615 susceptibility to enteric infection. *Cell Rep* 2021; **36**: 109457.
- 616 35 Mwaba J, Chisenga CC, Xiao S, *et al.* Serum vibriocidal responses when second doses of oral
617 cholera vaccine are delayed 6 months in Zambia. *Vaccine* 2021; **39**: 4516–23.
- 618 36 Ateudjieu J, Sack DA, Nafack SS, *et al.* An Age-stratified, Randomized Immunogenicity Trial of
619 Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon. *Am J Trop Med Hyg* 2022;
620 **107**: 974–83.